首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1677918

通用感染疾病市場規模、佔有率及成長分析（依疾病類型、治療類型、給藥途徑、最終使用者和地區）－2025-2032 年產業預測

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年03月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

通用感染疾病市場規模預計在 2023 年達到 416.5 億美元，並從 2024 年的 442.3 億美元成長到 2032 年的 715.7 億美元，預測期內（2025-2032 年）的複合年成長率為 6.2%。

據美國疾病管制與預防中心稱，通用感染疾病（由動物傳播給人類）預計每年將影響數以萬計的美國人。快速的都市化和人口成長可能會加劇這些問題，特別是在衛生條件較差的地區。此外，對動物性蛋白質和脂肪的需求不斷增加預計將推動通用感染疾病治療市場的發展。寵物的廣泛擁有在提供陪伴的同時也帶來了疾病傳播的風險。然而，新興國家認知度低、研究成本高等障礙可能會阻礙市場成長。然而，由於針對動物健康需求的創新治療方法的發展，預計未來幾年全球市場將會擴大。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

GlaxoSmithKline plc（UK）
Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Bayer AG（Germany）
Eli Lilly and Company（USA）
AbbVie Inc.（USA）
Gilead Sciences, Inc.（USA）
Bristol-Myers Squibb Company（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim GmbH（Germany）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Inovio Pharmaceuticals, Inc.（USA）
Emergent BioSolutions Inc.（USA）

結論和建議

簡介目錄

Product Code: SQMIG35I2117

Zoonotic Disease Treatment Market size was valued at USD 41.65 billion in 2023 and is poised to grow from USD 44.23 billion in 2024 to USD 71.57 billion by 2032, growing at a CAGR of 6.2% during the forecast period (2025-2032).

According to the Centers for Disease Control and Prevention, zoonotic diseases, transmitted from animals to humans, are projected to afflict tens of thousands of Americans annually. Rapid urbanization and population growth are likely to exacerbate these issues, especially in areas with poor sanitation. Additionally, the increasing demand for animal proteins and fats is expected to drive the market for zoonotic disease treatments. The prevalence of pet ownership provides companionship but also introduces the risk of disease transmission. However, barriers such as limited awareness in developing countries and high research costs could hinder market growth. Nonetheless, the global market is poised for expansion with the development of innovative therapies tailored to animal health needs in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is being propelled by a multitude of factors, including the surging occurrence of zoonotic diseases and a growing awareness of their transmission. Additionally, the continuous development of innovative and effective treatments, alongside supportive government initiatives, plays a significant role in market growth. Furthermore, technological advancements and a rise in investments directed toward research and development further contribute to the expansion of this market. Collectively, these elements underscore the urgent need for effective treatment options and underscore the importance of addressing zoonotic diseases in public health strategies.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential of the zoonotic disease treatment market, several factors may impede its progress. The limited availability of effective treatments and the high costs associated with these therapies are significant barriers. Additionally, insufficient investment in research and development presents a further challenge. The market's growth may also be affected by the rise of generic medications and the impending patent expirations of established brands. Furthermore, a shortage of skilled professionals and inadequate healthcare infrastructure in developing countries complicate the situation. High capital requirements for research and development, coupled with a general lack of public awareness, further restrain market expansion.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing a significant upward trend, propelled by the rising incidence of zoonotic infections linked to urbanization, deforestation, and climate change. As ecosystems are disrupted, the interaction between humans and wildlife intensifies, facilitating the transmission of pathogens. This surge in disease awareness is prompting an urgent demand for innovative treatments and vaccines. Furthermore, increased government funding for research and development, alongside advancements in biotechnology, are catalyzing market expansion. With a growing focus on preventative measures and rapid response strategies, the Zoonotic Disease Treatment market is poised for robust growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Rabies
Lyme Disease
Zika Virus
West Nile Virus
Hantavirus
Malaria
Tuberculosis
Relapsing Fever
Viral Hepatitis
Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Vaccines
Antiviral Drugs
Antibiotics
Immunoglobulins
Antibacterial Medication
Antifungal Medication
Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2025-2032)

Market Overview
Intravenous
Intramuscular
Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Ambulatory Surgical Centers
Homecare Settings
Research Institutions
Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2025-2032)

North America (Disease Type, Treatment Type, Administration Route, End User)
- US
- Canada
Europe (Disease Type, Treatment Type, Administration Route, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Administration Route, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments